The mycoplasma testing market size is estimated to be USD 792.1 million in 2022 and is expected to witness a CAGR of 13.52% during the forecast period 2023-2033. 792.1 Increasing R&D expenditures, growing healthcare costs, development of new technologies for medication research and development and improvements in cell culture technology are factors contributing to the market growth. Additionally, innovative techniques and large investments by key players and increase in respiratory tract diseases are expected to propel the market growth. However, high price of gene treatments and potential insertional mutagenesis is expected to hinder the growth.

Innovative techniques and large investments by key players are projected to propel the market growth. For instance, seven of the top ten best-selling medications in the first half of 2020 were biologics. This depicts the rise of biologics on the global market. A range of biologic products, including monoclonal antibodies, viral vaccines, and cytokines, which are used for medicinal or therapeutic purposes, are produced using cell lines. Cell line metabolism, physiology, and gene expression are significantly impacted by Mycoplasma strains.

Increase in respiratory tract diseases is predicted to fuel the market growth. Numerous pathogenic mycoplasma species are among the most frequently identified co-infections in a number of chronic diseases and medical disorders. The CDC reports that 152,657 people died in 2021 as a result of chronic lower respiratory diseases. The market for mycoplasma testing is anticipated to grow as a result of the rise in deaths from respiratory disorders, pulmonary diseases, and tuberculosis. Furthermore, leading market participants anticipate a rise in demand for better diagnostics for non-pulmonary therapies, which will propel the global market in the near future.

Segmentation

By Product

The market is categorized into kits & reagents, instruments, and services. In the global market, the kits & reagents segment accounted for the largest revenue share in 2022 owing to the high demand and high price for these products in mycoplasma detection. In response to the demands of researchers and biologic producers, a number of market participants have created mycoplasma detection kits, which is promoting segment growth. Instruments are expected to expand significantly throughout the anticipated time due to the easy availability of automated equipment for the detection of mycoplasma.

By Technology

The market is divided into ELISA, PCR, microbial culture techniques, enzymatic methods, indirect assay, and direct assay. In 2022, the PCR segment accounted for the highest revenue share due to the fact that this method enables the detection of numerous mycoplasma species while permitting the isolation of additional contaminating DNA. Easy use and quick identification are a few of the main advantages this technology can offer. For instance, the LookOut Mycoplasma PCR Detection Kit created by Merck KGaA makes it simpler to find contamination with Ureaplasma, Mycoplasma, and Acholeplasma in cell-derived biologicals and cell culture lines.

By Application

The market is segregated into end of production cells testing, virus testing, cell line testing, and others. In the global market, the cell line testing segment accounted for the largest revenue share in 2022 owing to rise in research projects being conducted in the field of cell culture. For instance, the Canadian Institutes of Health Research (CIHR), the country’s federal agency for funding health research, has provided approximately USD 981 million in funding to numerous Canadian health researchers. Numerous Canadian life science companies, particularly small and medium-sized companies engaged in product development and innovation, are receiving technical help from the National Research Council’s Industrial Research and Assistance Program (NRC-IRAP).

By End Use

The market is segmented into cell banks, pharmaceutical & biotechnology company, academic research institutes, contract research organizations, and others. In 2022, the pharmaceutical & biotechnology company segment accounted for the largest revenue share owing to substantial R&D investments made by these companies. To manage biological safety, these businesses conduct quality tests on raw materials. The prevalence of diseases including rheumatoid arthritis and psoriasis is also increasing, which is boosting the biopharmaceutical industry’s expansion. Contract research organizations (CROs) are expected to have profitable growth during the anticipated period as a result of the rising research services provided by these companies.

Regional Markets

In 2022, North America region accounted for the highest revenue in the mycoplasma testing market and is expected to maintain its dominance during the forecast period. This is attributed to its well-established healthcare sector and the rising prevalence of respiratory disorders. Additional factors supporting the rise of this region include the presence of global pharmaceutical and biotech companies and growing investment in R&D operations in the region. Asia Pacific is expected to exhibit an exponential CAGR throughout the anticipated time period due to rising healthcare spending and demand for better infrastructure for laboratory and clinical research. In addition, regulatory policies imposed by healthcare organizations that support enhancements in biosafety quality are likely to promote future growth potential.

Competitor Insights

Some of the key players operating in the mycoplasma testing market are American Type Culture Collection, Lonza Group AG, PromoCell GmbH, Charles River Laboratories International, Inc., Asahi Kasei Medical Co. Ltd., Thermo Fisher Scientific, Inc., Sartorius AG, InvivoGen, Merck KGaA, and Eurofins Scientific.

To achieve a competitive edge, these businesses are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Infinity Laboratories expanded its capabilities in April 2020 by starting to provide Mycoplasma testing.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, technology, application, and end use from 2023 to 2033.

Report Scope:

Segmentation: Mycoplasma Testing Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Kits & Reagents
• Instruments
• Services

Technology (Revenue, USD Million), 2022 – 2033

• ELISA
• PCR
• Microbial Culture Techniques
• Enzymatic Methods
• Indirect Assay
• Direct Assay

Application (Revenue, USD Million), 2022 – 2033

• End of Production Cells Testing
• Virus Testing
• Cell Line Testing
• Others

End Use (Revenue, USD Million), 2022 – 2033

• Cell Banks
• Pharmaceutical & Biotechnology Company
• Academic Research Institutes
• Contract Research Organizations
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA